Tetrofosmin
TETROFOSMIN — tetrofosmin injection, powder, lyophilized, for solution
AnazaoHealth Corporation
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
Dear Medical Professional,
Per your order, we have compounded Tetrofosmin as a sterile, freeze-dried preparation in a 10 mL vial. The characteristics of this preparation are described below.
DESCRIPTION
AnazaoHealth’s compounded Tetrofosmin vial is a sterile, non-pyrogenic preparation that consists of a lyophilized mixture of 0.35 mg of Tetrofosmin, 1.5 mg of D-Gluconate, 0.03 mg of Stannous Chloride Dihydrate, 0.48 mg of Disodium Sulphosalicylate, and 2.7 mg of Sodium Hydrogen Carbonate and is maintained under an inert nitrogen atmosphere. It contains no antimicrobrial preservative.
INDICATIONS
Tetrofosmin is a diagnostic agent used to assess areas of reversible myocardial ischemia in the presence or absence of infracted myocardium and is also used to assess ventricular function.
PHYSICAL HALF-LIFE & TARGET ORGANS
The physical half-life of technetium, Tc99m, is 6 hours and has a principal radiation emission of gamma photons with a mean energy of 140 KeV.
Absorbed radiation dose | ||||
Exercise | Rest | |||
Target organ | rad/mCi | µGy/MBq | rad/mCi | µGy/MBq |
Gall bladder wall | 0.123 | 33.2 | 0.180 | 48.6 |
Upper large intestine | 0.075 | 20.1 | 0.113 | 30.4 |
Bladder wall | 0.058 | 15.6 | 0.071 | 19.3 |
Lower large intestine | 0.057 | 15.3 | 0.082 | 22.2 |
Small intestine | 0.045 | 12.1 | 0.063 | 17.0 |
Kidney | 0.039 | 10.4 | 0.046 | 12.5 |
Salivary glands | 0.030 | 8.04 | 0.043 | 11.6 |
Ovaries | 0.029 | 7.88 | 0.035 | 9.55 |
Uterus | 0.027 | 7.34 | 0.031 | 8.36 |
Bone surface | 0.023 | 6.23 | 0.021 | 5.58 |
Pancreas | 0.019 | 5.00 | 0.018 | 4.98 |
Stomach | 0.017 | 4.60 | 0.017 | 4.63 |
Thyroid | 0.016 | 4.34 | 0.022 | 5.83 |
Adrenals | 0.016 | 4.32 | 0.015 | 4.11 |
Heart wall | 0.015 | 4.14 | 0.015 | 3.93 |
Red marrow | 0.015 | 4.14 | 0.015 | 3.97 |
Spleen | 0.015 | 4.12 | 0.014 | 3.82 |
Muscle | 0.013 | 3.52 | 0.012 | 3.32 |
Testes | 0.013 | 3.41 | 0.011 | 3.05 |
Liver | 0.012 | 3.22 | 0.015 | 4.15 |
Thymus | 0.012 | 3.11 | 0.009 | 2.54 |
Brain | 0.010 | 2.72 | 0.008 | 2.15 |
Lungs | 0.008 | 2.27 | 0.008 | 2.08 |
Skin | 0.008 | 2.22 | 0.007 | 1.91 |
Breasts | 0.008 | 2.22 | 0.007 | 1.83 |
Dose calculations were performed using the standard MIRD method (MIRD Pamphlet No.1 (rev),Society of Nuclear Medicine, 1976).
Effective dose equivalents (EDE) were calculated in accordance with ICRP 53 (Ann. ICRP 18 (1-4),1988) and gave values of 8.61 × 10-3 mSV/MBq and 1.12 × 10-2 mSV/MBq after exercise and rest, respectively.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.